Bavarian Nordic insiders sell shares
Analysis based on 6 articles · First reported Aug 25, 2026 · Last updated Sep 04, 2026
Insider sales by top executives could be perceived as a lack of confidence, potentially putting mild downward pressure on Bavarian Nordic's share price. However, the transactions are small relative to the company's size and may reflect personal financial planning, limiting the overall market impact.
In late August and early September 2026, several executives and board members of Bavarian Nordic A/S, a Danish vaccine company, disclosed transactions involving the company's shares. CEO Paul Chaplin sold 90,000 shares on August 24, 2026, at DKK 212.42 per share, totaling approximately DKK 19.1 million. Maria Tzatzaris, closely associated with Chaplin, sold 14,840 shares on August 21, 2026, at DKK 207.91 per share, totaling about DKK 3.1 million. On September 4, 2026, COO Russell Thirsk exercised warrants to subscribe to 28,590 new shares at DKK 190.11 per share and subsequently sold the same number of shares at DKK 215.4782 per share, realizing a gain. Board member Anja Gjøl sold 345 shares on September 3, 2026, at prices around DKK 222.00 and DKK 221.80. All transactions were conducted on Nasdaq Copenhagen. These insider sales may signal management's view of the stock's valuation, though the amounts are relatively modest compared to the company's market capitalization.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard